Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2214935119. doi: 10.1073/pnas.2214935119. Epub 2022 Nov 29.
The 53BP1-RIF1 pathway restricts the resection of DNA double-strand breaks (DSBs) and promotes blunt end-ligation by non-homologous end joining (NHEJ) repair. The Shieldin complex is a downstream effector of the 53BP1-RIF1 pathway. Here, we identify a component of this pathway, CCAR2/DBC1, which is also required for restriction of DNA end-resection. CCAR2 co-immunoprecipitates with the Shieldin complex, and knockout of CCAR2 in a BRCA1-deficient cell line results in elevated DSB end-resection, RAD51 loading, and PARP inhibitor (PARPi) resistance. Knockout of CCAR2 is epistatic with knockout of other Shieldin proteins. The S1-like RNA-binding domain of CCAR2 is required for its interaction with the Shieldin complex and for suppression of DSB end-resection. CCAR2 functions downstream of the Shieldin complex, and CCAR2 knockout cells have delayed resolution of Shieldin complex foci. Forkhead-associated (FHA)-dependent targeting of CCAR2 to DSB sites re-sensitized BRCA1-/-SHLD2-/- cells to PARPi. Taken together, CCAR2 is a functional component of the 53BP1-RIF1 pathway, promotes the refill of resected DSBs, and suppresses homologous recombination.
53BP1-RIF1 通路限制 DNA 双链断裂 (DSB) 的切除,并通过非同源末端连接 (NHEJ) 修复促进钝端连接。Shieldin 复合物是 53BP1-RIF1 通路的下游效应物。在这里,我们鉴定出该通路的一个组成部分 CCAR2/DBC1,它也需要限制 DNA 末端切除。CCAR2 与 Shieldin 复合物共免疫沉淀,并且在 BRCA1 缺陷细胞系中敲除 CCAR2 会导致 DSB 末端切除、RAD51 加载和 PARP 抑制剂 (PARPi) 耐药增加。CCAR2 的敲除与其他 Shieldin 蛋白的敲除具有上位性。CCAR2 的 S1 样 RNA 结合结构域是其与 Shieldin 复合物相互作用和抑制 DSB 末端切除所必需的。CCAR2 是 Shieldin 复合物的下游功能元件,CCAR2 敲除细胞中 Shieldin 复合物焦点的分辨率延迟。CCAR2 的 Forkhead-associated (FHA) 依赖性靶向到 DSB 位点使 BRCA1-/-SHLD2-/-细胞重新对 PARPi 敏感。总之,CCAR2 是 53BP1-RIF1 通路的功能组成部分,促进了已切除 DSB 的填充,并抑制了同源重组。